The company’s Q4 net profit also exceeded CNBC-TV18 poll estimates of ₹452.5 crore. Revenue rose 18.1% year-on-year to ₹6,606 crore from ₹5,592 crore, and was higher than CNBC-TV18 poll estimates of ₹6,447 crore.
EBITDA increased 31.3% year-on-year to ₹1,011 crore from ₹770 crore, surpassing CNBC-TV18 poll estimates of ₹936 crore. EBITDA margin stood at 15.3%, compared with 13.8% in the same quarter last year and against poll estimates of 14.5%.
Also Read: Apollo Hospitals Q3 Results: Profit up 35%, revenue beat estimates; dividend declared
Apollo Hospitals said its overall consolidated revenue for FY26 grew 16% to ₹25,228.5 crore, while EBITDA rose 25% to ₹3,769.3 crore. Consolidated profit after tax increased 34% to ₹1,941.5 crore during the year.
The company’s healthcare services revenue grew 16% in Q4FY26, driven by a 7% rise in inpatient volume, 4% increase in pricing and 5% improvement in case mix. In the CONGO-T segment, volume grew 8% while revenue increased 18% in the quarter, aided by clinical intensity. Average revenue per inpatient rose 9% year-on-year to ₹1.87 lakh in Q4FY26.
Apollo Hospitals commissioned four new hospitals during FY26. The company said pre-operative expenses and losses from new units stood at ₹41.4 crore in Q4FY26. EBITDA margin of established units expanded 105 basis points year-on-year to 25.5% from 24.4%.
Also Read: Apollo Hospitals shares may rally 33% from current levels; Citi cites attractive valuations
In the primary care segment, core revenues grew about 15% year-on-year in FY26, while preventive health-checkup volumes increased around 28%. Apollo Hospitals launched an international franchise clinic in Dhaka and introduced ProHealth in Dubai during the year. The company also added three owned clinics and 21 dialysis centres in FY26.
In diagnostics, Apollo Hospitals added 10 satellite labs and 279 collection centres to its network during FY26. The wellness segment grew about 34% year-on-year and contributed around 21% of diagnostics revenue.
The company said it implemented AI-enabled auto-validation in its newly launched CRL and achieved an average 77% auto-verification across 164 tests spanning six clinical specialties. It has processed more than 86 lakh tests so far.
In specialty care, Spectra revenue grew around 4% year-on-year in FY26, while Cradle revenue increased around 11%, and fertility business revenue rose around 6%.
Also Read: Apollo Hospitals Q2 profit beats estimates, up 25%; healthcare and digital arms lead growth
The board recommended a final dividend of ₹10 per equity share, equivalent to 200% of the face value of ₹5 per share, for FY2025-26, subject to shareholder approval at the ensuing Annual General Meeting.
The board has fixed August 14, 2026, as the record date for determining eligible shareholders for the final dividend and for the AGM. If approved at the AGM, the dividend will be paid on or before September 10, 2026.
The board, based on the recommendation of the Nomination and Remuneration Committee, also approved the re-appointment of Dr Prathap C Reddy as Executive Chairman for a further period of two years with effect from June 25, 2026, subject to shareholder approval at the AGM.
Shares of Apollo Hospitals Enterprise Ltd ended at ₹8,066.25, up by ₹40.25, or 0.50%, on the BSE.
